Randomized controlled trial2023Open access

Association of Body Weight With Response to Vitamin D Supplementation and Metabolism

Tobias DK, Luttmann-Gibson H, Mora S, Danik J, Bubes V, Copeland T, LeBoff MS, Cook NR, Lee IM, Buring JE, Manson JE

JAMA network open · 105 citations

How it was studied

Design
Randomized controlled trial (indexed by PubMed)
Studied in
People
Main outcome
Health markers and function

Who paid for it

Funding
Independent funding
Government
National Heart, Lung, and Blood Institute
Government
National Cancer Institute
Government
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Government
National Center for Complementary and Integrative Health
Government
NIAMS NIH HHS
Government
NHLBI NIH HHS
Government
NCI NIH HHS
Government
NCCIH NIH HHS
Grants
National Cancer Institute (R01 CA138962); National Cancer Institute (U01CA138962); National Heart, Lung, and Blood Institute (K24HL136852); National Center for Complementary and Integrative Health (R01 AT011729); National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR059775); National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR070854)

Based on 8 listed funder(s).

Publication

Published
2023-01-17 · JAMA Netw Open · vol. 6 · issue 1 · p. e2250681
Publisher
American Medical Association
Cited
226 citations · more than 100% of similar papers · 38.5× the field average
Impact
Top 10% most cited in its field
References
35 works
Access
Open access (journal) · CC-BY
Research areas
Vitamin D Research Studies · Nutrition, Genetics, and Disease · Nutritional Studies and Diet
Keywords
Vitamin D and neurology, Medicine, Body mass index, Internal medicine, Placebo, Vitamin, Cholecalciferol, vitamin D deficiency, Calcifediol, Parathyroid hormone, Cohort, Vitamin D-binding protein, Randomized controlled trial, Endocrinology, Physiology, Gastroenterology, Calcium
MeSH
humans, obesity, calcium, parathyroid hormone, vitamins, vitamin d, cohort studies, dietary supplements, aged, middle aged, female, male, overweight, biomarkers

11 authors

From US

  • Deirdre Kay Tobias · correspondingBrigham and Women's Hospital; Harvard University
  • Heike Luttmann‐GibsonBrigham and Women's Hospital; Harvard University
  • Samia MoraBrigham and Women's Hospital; Harvard University
  • Jacqueline Suk DanikHarvard University; Massachusetts General Hospital
  • Vadim Y. BubesBrigham and Women's Hospital; Harvard University
  • Trisha CopelandBrigham and Women's Hospital; Harvard University

Abstract

Importance

In the Vitamin D and Omega-3 Trial (VITAL), the effects of randomized vitamin D supplementation (cholecalciferol), 2000 IU/d, reduced the risk of several health outcomes among participants with normal, but not elevated, body weights. It was unclear whether weight had any association with the outcomes of the supplementation.

Objective

To investigate whether baseline body mass index (BMI) modifies vitamin D metabolism and response to supplementation.

Design, setting, and participants

VITAL is a completed randomized, double-blind, placebo-controlled trial for the primary prevention of cancer and cardiovascular disease. In the present cohort study, an analysis was conducted in a subset of VITAL participants who provided a blood sample at baseline and a subset with a repeated sample at 2 years' follow-up. VITAL was conducted from July 1, 2010, to November 10, 2018; data analysis for the present study was conducted from August 1, 2021, to November 9, 2021.

Interventions

Treatment outcomes of vitamin D, 2000 IU/d, supplementation vs placebo associated with clinical and novel vitamin D-related biomarkers by BMI category adjusted for other factors associated with vitamin D status.

Main outcomes and measures

Multivariable-adjusted means (SE) or 95% CIs of vitamin D-related serum biomarkers at baseline and follow-up: total 25-hydroxyvitamin D (25-OHD), 25-OHD3, free vitamin D (FVD), bioavailable vitamin D (BioD), vitamin D-binding protein (VDBP), albumin, parathyroid hormone (PTH), and calcium, and log-transformed as needed.

Results

A total of 16 515 participants (mean [SD] age, 67.7 [7.0] years; 8371 women [50.7%]; 12420 non-Hispanic White [76.9%]) were analyzed at baseline, including 2742 with a follow-up blood sample. Before randomization, serum total 25-OHD levels were incrementally lower at higher BMI categories (adjusted mean [SE]: underweight, 32.3 [0.7] ng/mL; normal weight, 32.3 [0.1] ng/mL; overweight, 30.5 [0.1] ng/mL; obesity class I, 29.0 [0.2] ng/mL; and obesity class II, 28.0 [0.2] ng/mL; P < .001 for linear trend). Similarly, baseline 25-OHD3, FVD, BioD, VDBP, albumin, and calcium levels were lower with higher BMI, while PTH level was higher (all P < .001 for linear trend). Compared with placebo, randomization to vitamin D supplementation was associated with an increase in total 25-OHD, 25-OHD3, FVD, and BioD levels compared with placebo at 2 years' follow-up, but increases were significantly lower at higher BMI categories (all treatment effect interactions P < .001). Supplementation did not substantially change VDBP, albumin, PTH, or calcium levels.

Conclusions and relevance

In this randomized cohort study, vitamin D supplementation increased serum vitamin D-related biomarkers, with a blunted response observed for participants with overweight or obesity at baseline. These longitudinal findings suggest that BMI may be associated with modified response to vitamin D supplementation and may in part explain the observed diminished outcomes of supplementation for various health outcomes among individuals with higher BMI.

Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).

Community trust

Loading…

How much do you trust this study's findings?

0 · not at all10 · completely

Comments

Sign in to rate, comment on or flag this study.Sign in

Something wrong here?

Flag this study if its information, labels or funding look wrong. An editor reviews every flag.

Sign in to rate, comment on or flag this study.Sign in

Educational information about published research. Not medical advice, and not a recommendation to start or stop anything.